Actelion Zavesca AWP
Executive Summary
Actelion/Celltech's oral Gaucher disease therapy Zavesca (miglustat) is priced at an AWP of $9,337 for a 30-day supply of 90 capsules. Zavesca was approved as second-line therapy to Genzyme's Cerezyme (imiglucerase) in July (1"The Pink Sheet" Aug. 4, 2003, p. 37). CuraScript has been selected as Zavesca's exclusive pharmacy distributor...